MedTrace Logo

Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

NCT02482961 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-06-26

No results posted yet for this study

Summary

This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin.

Conditions

  • Acinetobacter Infections

Interventions

DRUG

colistimethate sodium

At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory

Sponsors & Collaborators

  • DongGuk University

    lead OTHER

Principal Investigators

  • Young-Soon Yoon, professor · DongGuk University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-01-10
Completion
2018-04-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482961 on ClinicalTrials.gov